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rectal adenocarcinomas, 5 endometrial sarcomas, 8 melanomas, lung rest (mostly adenocarcinomas, 3 small cells and 1 synovial
sarcoma). 2 p no AP (age/technical impossibility) 7 men. Average age: 57 years (28–82).
Results. Radiotherapy techniques: 1-SS IMRT (beams/segments: 7/53), 5 VMAT-SA (1 SIB), 5 VMAT-DA and 19 RT-3D mean number
ﬁelds 15 (5-25). Schemes as characteristics of the case, the most used: 4×12Gy (other: 3×10, 8×6, 6×9). Average GTV volume:
15 cm3 (1.1–43), Average PTV volume: 50 cm3 (16.3–123). Well tolerated without acute registration. With a mean follow up of 13
months (1–48) have lost 2 and 3 patients died of disease at other levels, the remainder VCE but with local control (PET).
Conclusions. SBRT is a valid option compared to surgical resection of lung neoplasms. There are a lot of dose-fraction schemes
published (BED≥100Gy local control rates are high, 80–90%). Our results are consistent with those published. Tracking patients
we provide chronic toxicity data.
http://dx.doi.org/10.1016/j.rpor.2013.03.323
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Background. Stereotactic body radiotherapy (SBRT) has recently been used for the treatment of small lung tumors.
Purpose. To assess the initial response and toxicity of SBRT in patients with Stage I/II lung cancer and lung oligometastases.
Methods and materials. Between October 2009 and January 2013, 48 patients were treated with SBRT and tomotherapy. Median
follow-up was 6.6 months (2.5–21.3). Forty-one patients with Stage I/II lung cancer and 7 patients with oligometastases.
Histopathology was conﬁrmed in 72.9%. Localization: peripheral tumors (34 cases) and central tumors (14 cases). Median age was
72 years (55–85). More than 50% patients had severe medical comorbidities, 91.7% were inoperable tumors. Prescription dose:
50Gy in 10 fractions, 54Gy in 3 fractions or 60Gy in 3 fractions. Radiographic response and toxicity were evaluated according to
RECIST and RTOG criteria respectively. Metabolic response was evaluated according SUV in PET-TC.
Results. Radiological response in 39 patients at 3 months and 28 patients at 6 months with computed tomography were: 15.4%
and 35.7% complete, 48.7% and 39.3% partial, 33.3% and 17.8% stable disease and 2.6% and 7.2% progressive disease, respectively.
Local tumour control rate at 6 months (28 p) was 92.8%. Median SUV pre-SBRT was 7.6 (0–29.2) and post-SBRT at 6 months was 3
(0–6.9). Actuarial survival rates at 6 and 12 months were 89.6% and 76.9%, respectively. Two patients presented local relapse and
7 patients had regional or distance metastases. Early toxicity appeared in 3 patients: Grade 2 cough (2 p) and Grade 2 epithelitis
(1 p). Late toxicity in 3 patients: Grade 2 dyspnea (2 p) and symptomatic radiation pneumonitis (1 p).
Conclusion. Our preliminary results show that SBRT is well tolerated with good rates of local control and low toxicity for early
stage lung cancer and metastases in medically inoperable patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.324
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Introduction. The ﬁrst line treatment for early stage non-small cell lung cancer (T1-T2 N0 M0) is surgery, but 25% of patients do not
undergo surgery due to comorbidity or rejection. Several studies have published local control rates up to 85–95% with Stereotactic
Body Radiotherapy (SBRT), which is also an effective alternative for lung oligometastases. “Risk-adapted” dose fractionation
schedules seem to offer better tolerability. Evaluation of acute changes on CT after SBRT remains the subject of controversy and
requires an expert multidisciplinary team. PURPOSE: To analyze acute toxicity of patients treated with lung SBRT and to present
acute CT ﬁndings after 3 months of treatment.
Materials and methods. Between June 2012 and January 2013, 9 patients have been treated in our department with lung SBRT (5
primary tumors and 4 cases of colon-rectal lung metastases). “Risk-adapted” fractionation scheme was used. 4D simulation scan
with abdominal compression. Delineation of ITV with a margin of 3mm to create PTV. Daily Image Guided Radiotherapy with
CBCT.
Results. Median age 76 (67–86), Karnofsky 70–100%. Peripheral tumors in 7 cases (5×12Gy) and central tumors in 2 cases
(8×7.5Gy). Median tumor size 19.2mm (8–30), median PTV volume 27.5 cm3 (12.12–61.85). D2% 60.9Gy (56.7–63.8), D50% 60.6
(59.7–61.9), D98% 59.98Gy (57.3–63.7). Acute toxicity reported Grade 1 due to asthenia in one patient, and Grade 1 pulmonar
toxicity due to mild dyspnea in another patient. Evaluation with CT scan at 3 months: 1 case presented complete response, 2
cases presented stabilization of the nodes and 4 cases reduction of the node. PET scan were performed in 3 patients.
Conclusions. In our experience lung SBRT presents a low incidence of acute toxicity. Abdominal compression is well tolerated.
Persisting image on CT scan after 3 months of treatment creates uncertainty in the multidisciplinary team.
http://dx.doi.org/10.1016/j.rpor.2013.03.325
